Skip to main content

Travere Therapeutics, Inc. (TVTX)

NASDAQ: TVTX · IEX Real-Time Price · USD
27.61 -0.47 (-1.67%)
Dec 3, 2021 4:00 PM EST - Market closed

Company Description

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases.

Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria.

The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria.

It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome.

The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Travere Therapeutics, Inc.
Travere Therapeutics Logo
CountryUnited States
IndustryBiotechnology
SectorHealthcare
Employees262

Contact Details

Address:
3611 Valley Centre Drive
San Diego, CA 92130
United States
Phone888 969 7879
Website.travere.com

Stock Details

Ticker SymbolTVTX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code1438533

Key Executives

NamePosition
Dr. Eric M. Dube Ph.D.President, Chief Executive Officer and Director
Laura M. Clague CPAChief Financial Officer
Elizabeth E. ReedSenior Vice President, General Counsel and Corporate Secretary
Dr. William E. Rote Ph.D.Senior Vice President of Research & Development
Dr. Noah L. Rosenberg M.D.Chief Medical Officer
Sandra CalvinVice President, Corporate Controller and Principal Accounting Officer
Chris Cline C.F.A., CFASenior Vice President of Investor Relations and Corporate Communications
Casey LoganSenior Vice President of Corporate and Business Development
Laura M. JohnsonSenior Vice President of Human Resources
Peter HeermaChief Commercial Officer

Latest SEC Filings

DateTypeTitle
Nov 23, 2021CT ORDERConfidential treatment order
Nov 18, 20214Statement of changes in beneficial ownership of securities
Nov 9, 20214Statement of changes in beneficial ownership of securities
Nov 3, 20214Statement of changes in beneficial ownership of securities
Oct 28, 202110-QQuarterly report [Sections 13 or 15(d)]
Oct 28, 20218-KCurrent report
Oct 12, 20218-KCurrent report
Oct 8, 20214Statement of changes in beneficial ownership of securities
Oct 5, 20214Statement of changes in beneficial ownership of securities
Sep 23, 20213Initial statement of beneficial ownership of securities
View All SEC Filings